Florida Doc Loses DEA License Over Sketchy Pill Prescriptions Bust
Published Date: 7/25/2025
Notice
Summary
Dr. Taha Dias from Florida lost his DEA registration because he gave out controlled substance prescriptions in ways that broke the law between 2022 and 2023. Since he didn’t ask for a hearing, the DEA officially revoked his license, meaning he can’t prescribe these drugs anymore. This decision protects the public and took effect after the government’s final review in early 2025.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked — No Controlled Drugs
The DEA revoked Taha Dias, M.D.'s Certificate of Registration No. BD9971208, effective August 25, 2025. The Order says he can no longer prescribe controlled substances and that any pending applications to renew, modify, or obtain DEA registration in Florida are denied.
Default Admission for Failing to Seek Hearing
The record shows Dr. Dias did not request a hearing and was deemed in default under 21 CFR 1301.43; that default admitted the OSC's factual allegations. The Agency found he issued at least 18 prescriptions lacking a legitimate medical purpose between July 5, 2022 and December 4, 2023, including promethazine with codeine, oxycodone, and alprazolam.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
2026-20553, Decision and Order: Medpharm Research, LLC
Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.
Previous / Next Documents
Previous: 2025-14076, Committee on Equal Opportunities in Science & Engineering; Cancellation of Meeting
Heads up! The National Science Foundation’s Committee on Equal Opportunities in Science & Engineering has canceled their meeting that was set for October 30, 2025. If you were planning to join or follow their updates, no worries—just mark your calendar and stay tuned for future announcements. This change won’t affect any funding or deadlines right now.
Next: 2025-14078, Federal Secure Cloud Advisory Committee Notification of Upcoming Meeting
The Federal Secure Cloud Advisory Committee is holding a public meeting soon, and anyone interested can join or share their thoughts. This meeting affects government cloud security plans and could shape future tech rules. No costs or deadlines are announced yet, but staying tuned is a smart move!